Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD)

Open Access
Publisher Website
Google Scholar
Abstract
IBD is characterized by increased serum concentrations of different cytokines. IL‐10 inhibits the production of proinflammatory cytokines such as IL‐1, tumour necrosis factor‐alpha (TNF‐a), interferon‐gamma (IFN‐γ) and IL‐6 through inhibitory action on Th1 cells and macrophages, and it is thought to be a suppressor type cytokine. In the present study we determined serum concentrations of IL‐10 in patients with ulcerative colitis (UC) and Crohn's disease (CD). We measured human IL‐10 by our own newly established ELISA system using PharMingen antibodies. Serum antibodies were assessed in 44 patients with UC, 40 patients with CD, and in 30 healthy controls. Human IL‐10 serum levels were significantly increased in patients with active UC (144 ± 34 pg/ml (mean ± s.e.m.), P P r= 0.45, P r= 0.39, P r= 0.417, P r= 0.387, P <0.05) in patients with CD. Serum cytokine levels in patients with UC did not show any significant correlation to IL‐10 serum concentration. IL‐10 is elevated in serum of patients with active CD and UC. suggesting that IL‐10 acts as a naturally occurring damper in the acute inflammatory process of IBD.